Lipe & Dalton’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16K Hold
13
0.01% 93
2026
Q1
$12K Hold
13
0.01% 91
2025
Q4
$14K Buy
+13
New +$12.4K 0.01% 94
2024
Q4
Sell
-45
Closed -$40K 99
2024
Q3
$40K Sell
45
-11
-20% -$9.89K 0.02% 97
2024
Q2
$51K Hold
56
0.03% 93
2024
Q1
$44K Buy
56
+11
+24% +$7.83K 0.02% 97
2023
Q4
$26K Buy
+45
New +$26.3K 0.01% 98
2021
Q1
Sell
-100
Closed -$17K 102
2020
Q4
$17K Hold
100
0.01% 96
2020
Q3
$15K Hold
100
0.01% 94
2020
Q2
$16K Hold
100
0.01% 93
2020
Q1
$14K Hold
100
0.01% 95
2019
Q4
$13K Hold
100
0.01% 103
2019
Q3
$11K Sell
100
-10
-9% -$1.11K 0.01% 104
2019
Q2
$12K Hold
110
0.01% 97
2019
Q1
$14K Buy
+110
New +$13.4K 0.01% 77

Other funds holding LLY

Lipe & Dalton's LLY Position: Q2 2026 in Review

Lipe & Dalton held its Eli Lilly (LLY) position steady in Q2 2026 at 13 shares worth $16K. The position accounts for 0.01% of the portfolio, ranked #93.

Lipe & Dalton first reported a position in LLY in Q1 2019 and has held it in 15 quarters since. The position peaked at $51K in Q2 2024. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lipe & Dalton held 13 shares of Eli Lilly worth $16K as of Q2 2026.
  • Lipe & Dalton left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.01% of Lipe & Dalton's portfolio in Q2 2026, its #93 holding.
  • Lipe & Dalton first reported a position in Eli Lilly in Q1 2019 and has held it in 15 quarters since.
  • Lipe & Dalton's Eli Lilly position peaked at $51K in Q2 2024.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.